BioCentury | Jul 25, 2020
Translation in Brief

New class of cytosine base editors; plus new U.K. vaccine manufacturing facilities, scalable surrogate assay for COVID-19; combating antibiotic resistance and

...to accelerate mass production of a COVID-19 vaccine. Slated to open in December 2021 in Braintree...
BioCentury | Apr 5, 2016
Financial News

Human Longevity raises $220M series B

...with series A support from Illumina, Genting Group CEO KT Lim, DFJ partner Steve Jurvetson, BrainTree...
BioCentury | Mar 10, 2014
Finance

Venter's fellow travelers

...managing director at VC firm DFJ; BRJ Investments' Bryan Johnson, who founded online payment company Braintree...
BioCentury | May 6, 2013
Company News

Haemonetics, Hemerus Medical deal

...eligible for royalties on SOLX-based products with maximum royalties of $14 million. Haemonetics Corp. (NYSE:HAE), Braintree...
BioCentury | Apr 15, 2013
Clinical News

RenaGel phosphate binder data

...either RenaGel or PhosLo calcium acetate, the currently used phosphate binder standard ( Braintree Laboratories Inc. , Braintree...
BioCentury | Feb 11, 2013
Clinical News

Suprep regulatory update

...mixture of sodium, magnesium and potassium sulfates by year end. Ipsen has exclusive rights from Braintree...
...BioCentury, Oct. 19, 2009). Braintree markets the product in the U.S. as Suprep. Braintree Laboratories Inc. , Braintree...
BioCentury | May 7, 2012
Company News

Haemonetics, Hemerus Medical, Pall deal

...are slated to close in Haemonetics' second fiscal quarter ending Sept. 30. Haemonetics Corp. (NYSE:HAE), Braintree...
BioCentury | Jul 26, 2010
Company News

Biomet, Cytosol Laboratories Inc. deal

...Biomet Inc. , Warsaw, Ind. Cytosol Laboratories Inc. , Braintree, Mass. Business: Hematology Biomet will acquire...
BioCentury | Oct 19, 2009
Company News

Braintree, Ipsen deal

...Ipsen received exclusive rights to market Braintree's BLI-800 in the EU, Commonwealth of Independent States, China...
...includes marketed bowel cleanser Fortrans. Braintree is eligible for undisclosed milestones and royalties. Braintree Laboratories Inc. , Braintree...
BioCentury | Oct 22, 2007
Regulation

Sales of phosphate binders

...below. (A) For 2003, PhosLo sales from Aug. 4, when NABI acquired the product from Braintree...
Items per page:
1 - 10 of 31
BioCentury | Jul 25, 2020
Translation in Brief

New class of cytosine base editors; plus new U.K. vaccine manufacturing facilities, scalable surrogate assay for COVID-19; combating antibiotic resistance and

...to accelerate mass production of a COVID-19 vaccine. Slated to open in December 2021 in Braintree...
BioCentury | Apr 5, 2016
Financial News

Human Longevity raises $220M series B

...with series A support from Illumina, Genting Group CEO KT Lim, DFJ partner Steve Jurvetson, BrainTree...
BioCentury | Mar 10, 2014
Finance

Venter's fellow travelers

...managing director at VC firm DFJ; BRJ Investments' Bryan Johnson, who founded online payment company Braintree...
BioCentury | May 6, 2013
Company News

Haemonetics, Hemerus Medical deal

...eligible for royalties on SOLX-based products with maximum royalties of $14 million. Haemonetics Corp. (NYSE:HAE), Braintree...
BioCentury | Apr 15, 2013
Clinical News

RenaGel phosphate binder data

...either RenaGel or PhosLo calcium acetate, the currently used phosphate binder standard ( Braintree Laboratories Inc. , Braintree...
BioCentury | Feb 11, 2013
Clinical News

Suprep regulatory update

...mixture of sodium, magnesium and potassium sulfates by year end. Ipsen has exclusive rights from Braintree...
...BioCentury, Oct. 19, 2009). Braintree markets the product in the U.S. as Suprep. Braintree Laboratories Inc. , Braintree...
BioCentury | May 7, 2012
Company News

Haemonetics, Hemerus Medical, Pall deal

...are slated to close in Haemonetics' second fiscal quarter ending Sept. 30. Haemonetics Corp. (NYSE:HAE), Braintree...
BioCentury | Jul 26, 2010
Company News

Biomet, Cytosol Laboratories Inc. deal

...Biomet Inc. , Warsaw, Ind. Cytosol Laboratories Inc. , Braintree, Mass. Business: Hematology Biomet will acquire...
BioCentury | Oct 19, 2009
Company News

Braintree, Ipsen deal

...Ipsen received exclusive rights to market Braintree's BLI-800 in the EU, Commonwealth of Independent States, China...
...includes marketed bowel cleanser Fortrans. Braintree is eligible for undisclosed milestones and royalties. Braintree Laboratories Inc. , Braintree...
BioCentury | Oct 22, 2007
Regulation

Sales of phosphate binders

...below. (A) For 2003, PhosLo sales from Aug. 4, when NABI acquired the product from Braintree...
Items per page:
1 - 10 of 31